A study in men with biochemically recurrent prostate cancer and PSA doubling time = 9 months at the time of study entry.
This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS.
- AFT-47 ARACOG
A Phase II study comparing cognitive outcomes between men with non-metastatic and metastatic castration-resistant prostate cancer treated with darolutamide or enzalutamide.
- ALCHEMIST Trials (Alliance A151216, A081801 & ECOG E4512)
The ALCHEMIST trials are testing therapies that target two types of genetic changes that are thought to drive lung cancer growth: mutations in the EGFR gene and a rearrangement of the ALK gene.
- Alliance A011801
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1.
- Alliance A021502
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair.
- Alliance A021703 "SOLARIS"
This Alliance phase III trial looks at how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body.
- Alliance A031704 “PDIGREE”
A phase III trial in metastatic untreated renal cell cancer.
- Alliance A031902 (CASPAR)
A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (Lung-Map Sub-Study)
- Alliance A041702
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL).